Quantum Biopharma Class B Subordinate Voting Shares

QNTM

Market cap $22.1M

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.

AUSTIN, Texas, June 26, 2026 (GLOBE NEWSWIRE) -- via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled “Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis,” featuring Quantum BioPharma Ltd . (NASDAQ: QNTM) (CSE: QNTM).

NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork ), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.

NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork ), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.

Disseminated on behalf of  Quantum BioPharma , may include paid advertisements. AUSTIN, Texas, June 02, 2026 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.

TORONTO, June 02, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum” or the “Company”), a biopharmaceutical company focused on advancing innovative therapies and technologies, is pleased to announce that it has entered into an investor relations and consulting services agreement with Stocks.news through IR Agency LLC (the “Agency”) beginning on June 8, 2026.

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.

TORONTO, May 18, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum” or the “Company”), a biopharmaceutical company focused on advancing innovative therapies and technologies, today announced a significant milestone in its collaborative study with Massachusetts General Hospital (MGH): patient enrollment has reached the halfway mark, accompanied by encouraging preliminary imaging results.